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Abstract
Background: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended
for malaria prevention in HIV-negative pregnant women, but it is contraindicated in HIV-infected women taking daily
cotrimoxazole prophylaxis (CTXp) because of potential added risk of adverse effects associated with taking two antifolate
drugs simultaneously. We studied the safety and efficacy of mefloquine (MQ) in women receiving CTXp and long-lasting
insecticide treated nets (LLITNs).
Methods and Findings: A total of 1,071 HIV-infected women from Kenya, Mozambique, and Tanzania were randomized to
receive either three doses of IPTp-MQ (15 mg/kg) or placebo given at least one month apart; all received CTXp and a LLITN.
IPTp-MQ was associated with reduced rates of maternal parasitemia (risk ratio [RR], 0.47 [95% CI 0.27–0.82]; p= 0.008),
placental malaria (RR, 0.52 [95% CI 0.29–0.90]; p= 0.021), and reduced incidence of non-obstetric hospital admissions (RR,
0.59 [95% CI 0.37–0.95]; p= 0.031) in the intention to treat (ITT) analysis. There were no differences in the prevalence of
adverse pregnancy outcomes between groups. Drug tolerability was poorer in the MQ group compared to the control
group (29.6% referred dizziness and 23.9% vomiting after the first IPTp-MQ administration). HIV viral load at delivery was
higher in the MQ group compared to the control group (p= 0.048) in the ATP analysis. The frequency of perinatal mother to
child transmission of HIV was increased in women who received MQ (RR, 1.95 [95% CI 1.14–3.33]; p= 0.015). The main
limitation of the latter finding relates to the exploratory nature of this part of the analysis.
Conclusions: An effective antimalarial added to CTXp and LLITNs in HIV-infected pregnant women can improve malaria
prevention, as well as maternal health through reduction in hospital admissions. However, MQ was not well tolerated,
limiting its potential for IPTp and indicating the need to find alternatives with better tolerability to reduce malaria in this
particularly vulnerable group. MQ was associated with an increased risk of mother to child transmission of HIV, which
warrants a better understanding of the pharmacological interactions between antimalarials and antiretroviral drugs.
Trial registration: ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001813440
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Introduction
Many African pregnant women are infected with HIV, and
many of them are also exposed to falciparum malaria [1,2]. It is
estimated that at least 1 million pregnancies per year are
complicated by co-infection of malaria and HIV in sub-Saharan
Africa [3]. The interaction between malaria and HIV is
particularly deleterious in pregnant women, leading to increased
risk and severity of both malaria infection and disease [1,2]. In
addition, HIV infection attenuates the relative protection against
malaria acquired with subsequent pregnancies, placing more
women at risk for malaria-related complications [4,5]. Moreover,
HIV infection reduces the efficacy of malaria interventions and
complicates the use of antimalarials because of potential drug
interactions [6,7].
In Africa, intermittent preventive treatment in pregnancy
(IPTp) with sulfadoxine-pyrimethamine (SP) is recommended
monthly at each antenatal care (ANC) visit, along with the use
of insecticide treated nets, for malaria prevention in HIV-negative
pregnant women [8]. In areas where HIV prevalence among
pregnant women was higher than 10%, the WHO recommended
at least three IPTp-SP doses [9]. Moreover, in HIV-infected
pregnant women living in areas with limited health resources and
high HIV prevalence, universal cotrimoxazole prophylaxis
(CTXp) is recommended to prevent opportunistic infections
[10]. Since the risk of severe cutaneous reactions is increased in
individuals taking CTXp and SP concomitantly, and especially in
those who are HIV-infected, IPTp with SP is contraindicated in
HIV-infected pregnant women on CTXp [11,12]. In addition,
CTXp has been shown to protect against malaria infection and
illness in children [13] and in HIV-infected adults [14]. However,
the latter has not been adequately studied in pregnant HIV-
infected women. Thus, it is important to evaluate whether
provision of an antimalarial as IPTp in addition to CTXp is
needed to provide the most efficacious malaria prevention to the
most vulnerable pregnant women, those who are infected with
HIV.
Since SP cannot be evaluated in individuals on CTXp, other
antimalarials for IPTp should be considered. Candidate antima-
larials for IPTp should ideally have three main attributes: a long
half-life to maximize the prophylactic effect; be administered in
single dose to ensure adherence; and have a proven acceptable
reproductive toxicity safety profile. [11,12]. Among available
antimalarial drugs, mefloquine (MQ) offers the most comparative
advantages to SP for IPTp. This long-acting antimalarial (half-life
approximately 2–3 weeks) retains high efficacy in Africa [15–17],
and is considered safe throughout pregnancy as evidenced by its
recommendation by the WHO and the US Centers for Disease
Control and Prevention (CDC) for chemoprophylaxis for pregnant
women of all gestational ages travelling in malaria endemic
regions. MQ has also been recently reclassified as pregnancy
category B by the US Food and Drug Administration [18,19].
Notably, MQ has been reported to be associated with poor
tolerability, with frequent vomiting and dizziness, as well as mild
neurological and psychological adverse effects [20]. However, the
existing information on the safety and efficacy of MQ as IPTp is
limited in pregnant women, and even more so in those who are
HIV-infected [21–23].
We report here the results of a multicenter double-blind
placebo-controlled randomized trial conducted in three sub-
Saharan countries to evaluate the safety and efficacy of MQ as
IPTp in HIV-infected women taking daily CTXp and in the
context of long lasting insecticide treated nets (LLITNs).
Methods
Ethics Statement and Participants’ Safety
The study protocol and informed consent forms were reviewed
and approved by the Ethics Committees from the Hospital Clı´nic
of Barcelona (Spain), the US CDC, and the local regulatory
authorities and National Ethics Review Committees from Kenya,
Mozambique, and Tanzania (Table S1). Study participants signed
a written informed consent form prior to enrolment. The trial was
conducted under the provisions of the Declaration of Helsinki and
in accordance with Good Clinical Practices guidelines set up by
the WHO and by the International Conference on Harmoniza-
tion. An independent Data Safety Monitoring Board (DSMB) was
created prior to the trial and regularly reviewed and monitored the
safety data collected. The trial was registered prior to the
enrolment of the first participant in both the ClinicalTrials.gov
(NCT00811421) and the Pan African Clinical Trials
(2010020001813440) registries.
Study Area and Population
The study was conducted in three sub-Saharan countries:
Tanzania (Makole and Chamwino), Mozambique (Manhic¸a and
Maragra), and Kenya (Siaya). The characteristics of each site are
shown in Table S2. Enrolment started in March 2010 and was
completed in April 2012; the study follow-up ended in January 2013.
Study Design
An individually randomized double-blind placebo-controlled
trial was conducted to compare the efficacy of three monthly doses
of MQ as IPTp with placebo-IPTp in HIV-infected pregnant
women receiving daily CTXp in the context of LLITN use. The
primary endpoint of the study was the prevalence of peripheral
maternal malaria infection (microscopic or submicroscopic) at
delivery. Based on previous estimations in the study sites [7,24],
assuming a prevalence of peripheral parasitemia at delivery of
15% with CTX prophylaxis, it was estimated that 453 women per
arm were required to detect a decrease of 6.2% or more in the
prevalence of peripheral parasitemia in the CTX+IPTp-MQ
group (prevalence of 8.7%), with 80% power and 5% two sided
significance level. In order to allow 15% losses to follow-up, it was
calculated that 535 women/study arm had to be recruited (Texts
S1 and S2).
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Enrolment and Interventions
Pregnant women of all gravidities attending the ANC clinic
for the first time and who had not received IPTp during their
current pregnancy were given the opportunity to be included in
the study after providing informed consent. Enrolled women
were permanent residents in the area, had a gestational age #28
weeks, had a positive HIV-test at recruitment, absence of history
of allergy to sulfa drugs or MQ, absence of history of severe
renal, hepatic, psychiatric, or neurological disease, and had not
received MQ or halofantrine treatment in the preceding four
weeks. In Mozambique and Tanzania, HIV-negative women
were invited to participate in a randomized controlled trial
evaluating the safety and efficacy of MQ IPTp compared to SP
IPTp [25]. Gestational age was determined from fundal height
measured by bimanual palpation. Following national guidelines
in place, HIV status was assessed after voluntary HIV
counselling and testing with an HIV rapid test and the positive
results confirmed with a second rapid test (details of the rapid
tests used are available in Table S2). Haemoglobin (Hb) and the
syphilis rapid plasma reagin (RPR) test were assessed as part of
routine ANC on fingerprick collected capillary blood, and 5 ml
venous blood was taken for CD4+T cell count and viral load
determination. Women were recruited regardless of their
immunosuppression level (as measured by CD4+T cell count)
or whether or not they were already on antiretroviral therapy
(ART) for their own health.
The allocation of the participants to the study arms was
done centrally by block randomization (block size of 6)
stratified by country to receive CTX (Septrin, UCB Pharma,
fixed combination 800 mg of trimethroprim and 160 mg of
sulfamethoxazole/tablet) plus IPTp-MQ (Lariam, Roche,
250 mg of MQ base/tablet) or CTX plus IPTp-placebo
(identical to MQ tablets in shape and colour). The Pharmacy
Department of the Hospital Clinic in Barcelona produced and
safeguarded the computer-generated randomization list for
each recruiting site until unblinding, and carried out the
masking, labelling, and packaging of all study interventional
drugs. Study number allocation for each participant was
concealed in opaque sealed envelopes that were sequentially
numbered and opened only after recruitment by study health
personnel. Study participants were assigned a unique study
number linked to the allocated treatment group. Investigators,
laboratory staff, care providers, and study participants were
blinded to intervention throughout the study. All participants
received a LLITN (PermaNet, Vestergaard Fransen) at
enrolment as part of the study intervention.
Following physical examination, recruited women with
gestational age $13 weeks received the first administration
of IPTp (either placebo or MQ) under supervision. The
number of tablets administered was calculated based on the
participant’s body weight at the first IPTp administration at a
dosage of 15 mg/kg, assuming that each tablet contained
250 mg of active principle (MQ or placebo). The maximum
dosage provided did not exceed 1,500 mg of MQ base. The
administration of the study IPTp drugs was supervised and
participants were observed for 60 minutes following IPTp
administration. Women vomiting within the first 30 minutes
were given a second full IPTp dose; those vomiting after 30–
60 minutes were given an additional half dose. If the
replacement dose was also vomited, study drug dosing was
interrupted and routine ANC guidelines followed. The second
and third administrations of IPTp-MQ/placebo were given at
least one month apart. All women also received study CTX
tablets on a monthly basis for daily prophylaxis.
Follow-up
Drug tolerability was assessed immediately and two days after
intake by home visits of field workers. Adherence to CTXp
(measured by self-reported use and by counting the remaining
number of tablets) and to LLITNs (assessed by self-reported use
the preceding night) was evaluated at every monthly ANC visit, as
well as during all unscheduled visits. Women were encouraged to
attend the study health facility whenever they had any health
complaint. Health care was free of charge and in general there was
little availability of antimalarial drugs over the counter at all sites.
A health facility-based passive surveillance system was established
at each site to capture unscheduled visits of study participants
during study follow-up. At each unscheduled visit, a standardized
questionnaire was completed documenting signs and symptoms.
Blood smears were prepared for malaria parasite examination and
Hb was measured if there were current or reported symptoms
and/or signs suggestive of malaria. Clinical malaria episodes were
treated with oral quinine (first trimester) or artemether-lumefan-
trine (subsequent trimesters) for uncomplicated malaria; parenteral
quinine was used for treatment of severe malaria. Solicited and
unsolicited adverse events (AEs) were assessed. The former was
done by directed questioning of malaria related signs and
symptoms during unscheduled visits, whereas the latter were
assessed through open questioning during scheduled visits. HIV/
AIDS management of study participants was provided by the local
government health services according to national guidelines [26–
28]. Administration of antiretroviral (ARV) drugs for prevention of
mother to child transmission of HIV (PMTCT) or ART was
registered in the study concomitant medication forms.
At delivery, a sample from the mother’s peripheral blood was
collected for Hb, CD4+T cell count, HIV viral load, and malaria
infection evaluation; cord blood and placental samples (biopsy and
impression smears) were also taken, as well as blood onto filter
paper for qPCR determinations. Newborns were weighed
(including stillbirths) and measured and their gestational age at
birth assessed using the Ballard’s score [29]. Babies’ weights not
captured at birth were estimated from weights obtained in the first
week of life using a regression model [30]. Six weeks after the end
of pregnancy, a capillary blood sample from the mother was
collected for malaria parasite determination. Infants born to study
participants were followed until two months after birth to assess
survival and general morbidity. Following national guidelines for
PMTCT of HIV, a capillary blood sample was collected from the
infant at six weeks of age onto filter paper for HIV PCR analysis.
Laboratory Methods
Maternal HIV and syphilis serostatus were assessed at each site
according to local standard procedures using rapid diagnostic tests
(Table S2). CD4+T cell count was determined by flow cytometry
after staining of whole blood with CD3, CD8, and CD4
fluorochrometolabelled antibodies and acquisition using FACS-
Calibur (BD Biosciences) and TruCOUNT tubes (Becton Dick-
inson). HIV viral load was determined from plasma cryopreserved
at 280uC using the COBAS AMPLICOR or AmpliPrep (Roche
Diagnostics) devices; these assays have a lower detection limit
ranging from 50 to 400 copies per millilitre. Hb levels were
determined using mobile devices (HemoCue [www.eurotrol.com]
and Hemocontrol [www.ekfdiagnostics.com]) on capillary blood
samples. Plasmodium falciparum parasites were identified by
microscopy on Giemsa-stained blood films according to standard,
quality-controlled procedures [31–33]. P. falciparum-specific real
time quantitative PCR (RT-qPCR) was performed on maternal
peripheral and placental samples, with the inclusion in all
reactions of a negative control with no template DNA [34].
Prevention of Malaria in Pregnancy in HIV-Infected Women
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Tissue samples were collected from the maternal side of the
placenta and fixed with 10% neutral buffered formalin. Biopsies
were processed, stained, and examined following standard
procedures [35]. Impression smears from the placenta were
stained with Giemsa’s staining and read following a standardized
protocol [36].
Data Management, Statistical Methods, and Definitions
The quality of the data recorded in the study source documents
and case report forms (CRFs) were monitored regularly following
the principles of Good Clinical Practices by the trials’ clinical
monitor before their shipment to the centralized database. Data
were double-entered using the OpenClinica Enterprise software
for clinical data management (www.openclinica.com). The main
analysis was done on the Intention-to-Treat (ITT) cohort that
included all recruited women that met the inclusion criteria and
had data on the specific outcomes, and on the According to
Protocol (ATP) cohort that included all women who had received
three doses of IPTp according to the pre-specified schedule, and
have results available on peripheral parasitemia at delivery. The
safety cohort was defined as all recruited women who had received
at least one dose of IPTp and whose data for analysis were
available. The analysis of safety and tolerability was made on the
Safety cohort. The ITT analyses were adjusted by country. The
analyses in the ATP cohort were adjusted by country only and by
baseline covariates (country, gestational age, gravidity, anemia,
literacy, middle upper arm circumference [MUAC], and CD4+T
cell count). The proportion of women with asexual P. falciparum
parasitemia (either microscopic or submicroscopic) was compared
between groups using a modified binomial regression [37]. The
statistical analysis plan is available in Text S3. Findings of all study
outcomes listed in the protocol (Text S1) are reported in the results
section and the tables.
Peripheral malaria infection at delivery (primary study endpoint)
was defined as the presence of asexual P. falciparum parasites of any
density in a blood smear or filter paper (detected either by optical
microscopy or PCR, respectively). Heterogeneity between countries
for the primary endpoint was evaluated using a Wald test. A clinical
malaria episode was defined as presence of P. falciparum parasites
in a blood smear plus any sign or symptom suggestive of malaria
including: current fever (axillary temperature$37.5uC) or history of
fever in the last 24 hours, and/or pallor, and/or arthromyalgias
and/or headache, and/or history of convulsions [38]. The
incidence of all-cause hospital admissions and all-cause outpatient
attendance was analyzed using negative binomial regression. The
same statistical method was used for the exploratory analysis of non-
obstetric causes of hospital admission. The incidence of all clinical
malaria episodes was compared between groups also using a
Figure 1. Trial profile (ITT cohort).
doi:10.1371/journal.pmed.1001735.g001
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negative binomial regression allowing for interdependence between
episodes within the same subject, excluding from the time at risk the
28 days after the end of treatment for a malaria episode. Detection
of parasites in blood samples by RT-qPCR where the correspond-
ing blood smear was read as negative was defined as submicroscopic
P. falciparum infection.
Placental infection was defined as the presence of parasites with
or without pigment detected by histological examination, impres-
sion smear [35] or PCR [34]. Maternal anemia was defined as a
Hb level ,11 g/dl and severe anemia as Hb,7 g/dl, while fetal
anemia was defined as a cord blood Hb level ,12.5 g/dl. CD4+T
cell count was categorized as #350 or .350 cells/ml. Maternal
viral load at delivery was analyzed in the logarithmic scale using
censored regression (Tobit regression) including as censored values
those that were lower than 400 copies/ml [39,40]. Coefficients of
the regression were transformed back to original scale and
presented as proportional difference between groups. Adherence
with CTXp was evaluated independently in each country using
the Wilcoxon Rank sum test. Ordered polytomous logistic
regression on the tertiles of CTXp adherence was used to evaluate
the adherence by intervention group adjusting by country (and
other baseline covariates in the ATP analysis). Participant’s
adherence with PMTCT or ART was estimated from self-
reporting and using the concomitant medication registry, and
classified as follows: complete, ARVs received antenatally,
intrapartum, and postpartum, in accordance to national guidelines
Table 1. Baseline characteristics.
Variables Control MQ
Participants N 537 534
Countrya Kenya 234 (44) 231 (43)
Mozambique 280 (52) 281 (53)
Tanzania 23 (4) 22 (4)
Age (years)b 26.6 (5.4) [536] 26.8 (5.8) [533]
Gravidity (categories)a Primigravidae 51 (9) 57 (11)
1–3 previous pregnancies 363 (68) 341 (64)
4 or more pregnancies 122 (23) 136 (25)
Weight (kg)b 59.8 (8.1) [537] 60.2 (8.8) [534]
Height (cm)b 161.1 (7.4) [537] 161.3 (8.3) [532]
MUAC (cm)b 26.9 (2.6) [534] 26.9 (3.1) [528]
Gestational age (weeks)c 21.0 (7.0) [537] 21.0 (8.0) [534]
Gestational age in categoriesa First trimester 70 (13) 62 (12)
Second trimester 340 (63) 343 (64)
Third trimester 127 (24) 129 (24)
Literate (can read and/or write)a No 111 (21) 91 (17)
Yes 426 (79) 443 (83)
Syphilis testa Positive 25 (5) 29 (5)
Negative 510 (95) 501 (94)
Hb (g/dl)b 10.2 (1.7) [535] 10.1 (1.8) [533]
Overall anemia (Hb,11 g/dl) at baselinea No 191 (36) 169 (32)
Yes 346 (64) 365 (68)
Viral load categories (copies/ml)a Undetectable 109 (20) 120 (22)
400–999 130 (24) 122 (23)
1,000–9,999 167 (31) 169 (32)
.9,999 101 (19) 91 (17)
CD4 categories (c/ml)a #350 206 (38) 197 (37)
.350 310 (58) 316 (59)
Start ART after recruitmenta No 72 (14) 90 (17)
Yes 193 (37) 175 (33)
ART indicated at baseline 263 (50) 262 (50)
On ART at baseline 119 (22) 130 (24)
ITT cohort.
an (column percentage).
bArithmetic mean (SD) [n].
cMedian (IQR) [n].
MUAC, middle upper arm circumference.
doi:10.1371/journal.pmed.1001735.t001
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[26–28]; incomplete, if ARVs received partially only; or nothing, if
no ARVs were registered or reported. The proportion of HIV-
infected infants was compared between groups using a similar
methodology to that used for the primary outcome [34]. As an
exploratory analysis to evaluate possible confounders on the rates
of MTCT transmission of HIV, a univariate analysis for selected
variables (namely PMTCT adherence, type of delivery [c-section
versus vaginal], health facility delivery, presence of moderate
vomiting as AE, drug-related vomiting, maternal hospital admis-
sions, clinical malaria during pregnancy, placental infection, RPR
test result at baseline, and viral load at delivery) was performed
and only those statistically significant variables (p,0.05) were
included in the multivariate model.
Immediate tolerability to study drugs was assessed as observed
vomiting within one hour of drug administration. An AE was
defined as any untoward medical occurrence in a study
participant, to whom the study drug was administered, including
occurrences, which were not necessarily caused or related to that
drug. Serious adverse events (SAEs) were defined as an AE that
meets any of the following criteria: (a) results in death, (b) is life-
threatening, (c) requires hospitalization (or prolongation of existing
hospitalization), (d) results in disability/incapacity, (e) is a
congenital anomaly, or (f) any event of special interest (including
cutaneous and neuropsychiatric events, miscarriages, and still-
births of women not admitted to hospital) [41]. The proportions of
women with an AE or a SAE were presented by treatment group
with 95% exact confidence intervals. For safety and tolerability
outcomes it was considered that there was no evidence of
significant difference between treatment groups if the 95%
confidence intervals overlapped. Data analysis was performed
using Stata statistical software version 13 (Stata Corp.).
Results
Figures 1 and S1 show the trial profiles for the ITT and the
ATP cohorts. Overall, 1,071 pregnant women were randomized to
receive IPTp (537 were allocated to control and 534 to MQ).
Tanzania contributed with 45 participants only because of
competitive recruitment with another study in the area. The
main reasons for non-enrolment into the trial were baseline HIV
test negative (52.5%), no permanent residence in the study area
(24.5%), and gestational age .28 weeks (12.5%). The overall
refusal rate for trial participation was 6.5%. Baseline character-
istics were similar between treatment groups (Table 1). Mean
gestational age was 21 weeks (standard deviation [SD] 7) at the
first IPTp dose, 26 weeks (SD 6) at the second IPTp dose, and 29
weeks (SD 6) at the third IPTp dose. Median time between the first
and the second IPTp dose was 32 days (IQR 2), 31 days (IQR 2)
between the second and the third, and 62 days (IQR 49) between
the last dose and delivery. The second IPTp dose was not given to
4.7% and 7.8% of women who had received the first dose of
placebo and MQ, respectively. The third dose was not given to
7.5% and 10.6% of the women who had received the second dose
of placebo and MQ, respectively. The reasons for not receiving
IPTp doses are shown in the trial profile (Figure 1). Overall,
adherence to CTXp was high with over 66% of pregnant women
taking 87% or more of the expected dosages (75% took 80% or
more) and with no significant differences between groups
(Table 2). Compared with Kenya, the odds of being in a higher
category of adherence to CTXp was lower in Mozambique (odds
ratio [OR] 0.31, [95% CI 0.24–0.39]; p,0.001) or in Tanzania
(OR, 0.16, [95% CI 0.09–0.30]; p,0001). The OR of being in a
higher category of adherence to CTXp in the MQ group
compared with the placebo group was 0.86 ([95% CI 0.68–
1.09]; p= 0.203) and there was no interaction between country
and intervention group (Chi-square 0.33 with 2 degrees of
freedom [df]; p= 0.846).
Primary Endpoint
A total of 973 peripheral blood samples from women at delivery
were collected (490 from control and 483 from MQ group). The
prevalence of peripheral maternal malaria infection at delivery was
significantly lower in women receiving IPTp-MQ compared to
those who received IPTp-placebo (7.6% in the control group and
3.5% in the MQ group; risk ratio (RR) 0.47 [95% CI 0.27–0.82];
p= 0.008) (no interaction between country and treatment group
was found [Chi-square 4.27 with 2 df; p= 0.11]). Similar results
were found in the ATP analysis (Table 3).
Secondary Endpoints
The frequency of placental infection was significantly lower in
the MQ group (3.8%) compared to the control group (7.4%) (RR,
0.52, [95% CI 0.29–090]; p= 0.021). There were no significant
differences between groups in the prevalence of maternal and fetal
anemia, prevalence of low birth weight, or in the prevalence of
fetal and maternal parasitemia one month after delivery (Table 3).
At delivery, in the ITT analysis the proportion of women with low
maternal CD4+T cell count and the distribution of viral load were
Table 2. Adherence to cotrimoxazole categorized in tertiles.
CTX Adherence Control MQ ORa (95%CI) p-Value
n Percent n Percent
ITT 0.87 (0.89–1.09) 0.217
Tertile 1 (0%,87%) 161 31.5 176 35.2
Tertile 2 (87%,100%) 130 25.4 124 24.8
Tertile 3 (100%) 220 43.1 200 40.0
ATP 0.99 (0.77–1.27) 0.952
Tertile 1 (0%,87%) 133 30.1 127 30.5
Tertile 2 (87%,100%) 119 26.9 110 26.4
Tertile 3 (100%) 190 43.0 179 43.0
aOR of being in a given category or superior. ITT adjusted by country. ATP analysis adjusted by baseline variables (country, literacy, gestational age, gravidity, anemia,
middle upper arm circumference, and CD4). Interaction MQ6country, p-value = 0.842 for ITT, p-value = 0.771 for ATP cohort.
doi:10.1371/journal.pmed.1001735.t002
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similar between groups. In the ATP analysis the viral load
distribution in the MQ group was 1.61 times (95% CI 1.00–2.59)
higher than in the control group (p= 0.048) (Table 4).
The incidence of hospital admissions that were either all-cause or
only due to non-obstetric causes was lower in the women receiving
MQ compared to those receiving placebo (RR, 0.65, [95% CI 0.41–
1.03]; p= 0.065) and (RR, 0.59, [95% CI 0.37–0.95]; p= 0.031),
respectively. The incidences of clinical malaria and all-cause
outpatient attendance during the study follow-up tended to be lower
in women receiving MQ than in those receiving placebo, although
these differences were not statistically significant (RR, 0.52, [95% CI
0.22–1.21]; p= 0.128; and RR, 0.86 [95% CI 0.72–1.03]; p= 0.098,
respectively) (with similar results in the ATP analysis) (Table 5; Figure
S2). Overall, no differences were found between the ATP unadjusted
and the ATP adjusted analyses.
The overall reported use of LLITNs at delivery was of 93% and
of 98% one month after the end of pregnancy, with no difference
between study groups.
Safety
There were no differences in the prevalence of miscarriages,
stillbirths, premature births, and congenital malformations
between groups (Table 6). The number of SAE, including
maternal and neonatal deaths, was also similar between study
arms. None of the reported SAEs were considered to be drug-
related by the clinical investigator assessing the participant.
Tolerability
The overall immediate tolerability of IPTp was poorer in the
MQ group (25 episodes of vomiting in the first hour following
IPTp administration) as compared to placebo (one episode of
vomiting) (Table 7). The most frequently reported AEs following
the first IPTp administration were dizziness, vomiting, nausea, and
headache in both groups. These frequencies were significantly
higher in the MQ group as compared to the control group and
were reduced in the subsequent second and third IPTp
administrations (Table 8). The majority of the reported related
AEs were mild (Table 9).
Mother to Child Transmission of HIV
Given the observed difference between the treatment groups
in viral load at delivery, a more detailed analysis of the mother
to child transmission (MTCT) of HIV at 6 weeks of age (median
5.9 weeks, IQR 1.7) was performed. The proportion of infants
with an HIV DNA positive PCR was higher in those born to
women who had received MQ compared to those who had
received placebo (RR, 1.95, [95% CI 1.14–3.33]; p = 0.015;
with similar results in the ATP analysis) (Table 10). There was
no difference in the proportion of mother-infant pairs with
complete PMTCT of HIV or ART regimen by treatment group
based on registry examination (233/435 [54%] in the control
group and 249/420 [59%] in the MQ group). Table 11 shows
the concomitant ARV medication received by treatment group.
There was no difference in the mode of delivery by group (6%
underwent a C-section in the control group and 5% in the MQ
group), nor in the proportion of hospital deliveries (86% in both
intervention groups). Reported vomiting (either related or not,
or severe) was not associated with increased viral load (p = 0.81),
nor with the risk of MTCT of HIV (p = 0.655). In contrast,
clinical malaria during pregnancy was found to be associated
with an increased risk of MTCT of HIV. Higher viral loads at
delivery were also associated with increased risk of MTCT of
HIV (Table 12).
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Discussion
This placebo-controlled trial of IPTp with MQ (15 mg/kg dose
three times at least one month apart) in HIV-infected pregnant women
in the context of daily CTXp and LLITN use found significant
reductions in the risk of important parameters of malaria infection in
pregnancy such as maternal parasitemia at delivery and placental
infection. In addition, IPTp-MQ was associated with reduction in the
incidence of non-obstetric hospital admissions while the incidence of
all-cause out-patient visits, all-cause hospital admissions, and clinical
malaria during pregnancy also tended to be lower in women receiving
IPTp-MQ. The safety profile in terms of SAEs and adverse pregnancy
outcomes was similar between the two study groups, and there were no
reported SAEs related to the medication. On the other hand,
tolerability of MQ was poor compared to the placebo group especially
for the AEs that have been commonly reported with this drug such as
dizziness and vomiting. MQ IPTp was also associated with an
increased risk of MTCT of HIV.
Reduced frequency of placental malaria in MQ recipients was
also reported in an open-label trial comparing CTXp and IPTp-
MQ plus CTXp in 292 HIV-infected Beninese women [23]. In the
present study, IPTp-MQ was associated with a reduction in the
incidence of morbidity outcomes both overall and malaria-related,
and this finding was consistent with a reduction in the incidence of
non-obstetric admissions, which were mainly caused by infectious
causes. HIV-infected pregnant women have an increased risk of
suffering and dying from infectious diseases [42–45]. On the other
hand, it is well known that malaria infection causes immunosup-
Table 7. Immediate medication tolerability (safety cohort).
Adverse Event Control MQ
n Percent 95% CI n Percent 95% CI
1st IPTp administration
Vomiting within 30 min 0 0.0 (0.00–0.69) 6 1.2 (0.42–2.48)
Vomiting within 60 min 0 0.0 (0.00–0.69) 6 1.2 (0.42–2.48)
Vomiting replacement dose 0 0.0 (0.00–0.69) 3 0.6 (0.12–1.67)
2nd IPTp administration
Vomiting within 30 min 0 0.0 (0.00–0.73) 6 1.2 (0.46–2.69)
Vomiting within 60 min 0 0.0 (0.00–0.73) 4 0.8 (0.23–2.11)
Vomiting replacement dose 0 0.0 (0.00–0.73) 4 0.8 (0.23–2.11)
3rd IPTp administration
Vomiting within 30 min 1 0.2 (0.01–1.18) 2 0.5 (0.06–1.67)
Vomiting within 60 min 0 0.0 (0.00–0.79) 1 0.2 (0.01–1.29)
Vomiting replacement dose 0 0.0 (0.00–0.79) 0 0.0 (0.00–0.85)
doi:10.1371/journal.pmed.1001735.t007
Table 8. Most frequent medication related adverse events (safety cohort).
Adverse Event Control MQ
n Percent 95% CI n Percent 95% CI
1st IPTp administration
Dizziness 40 7.5 (5.43–10.10) 155 29.6 (25.75–33.75)
Vomiting 16 3.0 (1.73–4.84) 125 23.9 (20.31–27.79)
Nausea 21 4.0 (2.46–5.97) 54 10.3 (7.85–13.26)
Headache 40 7.5 (5.43–10.10) 38 7.3 (5.19–9.84)
2nd IPTp administration
Dizziness 17 3.4 (1.97–5.31) 86 17.8 (14.53–21.56)
Vomiting 11 2.2 (1.09–3.85) 76 15.8 (12.63–19.33)
Nausea 8 1.6 (0.68–3.09) 29 6.0 (4.07–8.53)
Headache 23 4.5 (2.90–6.73) 29 6.0 (4.07–8.53)
3rd IPTp administration
Dizziness 9 1.9 (0.88–3.61) 42 9.7 (7.11–12.94)
Vomiting 12 2.6 (1.33–4.43) 36 8.4 (5.92–11.38)
Nausea 3 0.6 (0.13–1.86) 24 5.6 (3.60–8.17)
Headache 24 5.1 (3.31–7.52) 30 7.0 (4.75–9.79)
doi:10.1371/journal.pmed.1001735.t008
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pression, increasing the risk and severity of other infections [3,46].
This increased risk of immunosuppression is supported by the
findings of several studies testing malaria preventive interventions
in children that have shown a reduction in overall (not just
malaria-specific) morbidity and mortality due to malaria preven-
tive interventions in children [47]. Thus, it is possible that the
decreased risk of malaria infection in women who took MQ had
an impact in reducing the incidence and/or severity of other
infections. It may also be speculated that women receiving MQ
were less likely to go to the health facility because they were more
likely to suffer AEs (mainly dizziness and vomiting). Although we
do not have information to refute this possibility, it seems unlikely
that these AEs that were generally mild and transient would have
prevented severely ill women from attending the health facility.
The poor tolerability of MQ compared to placebo found in this
study has been reported previously [48] and in a recent trial of
IPTp with the same MQ dose among HIV-negative pregnant
women [25]. This finding is in contrast with the results from a
double-blind placebo-controlled trial of MQ prophylaxis using a
different regimen and lower dose (250 mg/weekly for one month
followed by 125 mg/weekly until delivery) among pregnant
women from Thailand, where similar rates of adverse effects were
reported among the placebo and the MQ group [48]. In the
present study, MQ tolerability appeared to improve with each
subsequent dose of MQ. The reduced frequency of reported AEs
with repeated number of administrations has been observed in
other studies of MQ among pregnant women but also in non-
pregnant women travelling in malaria endemic regions [21,49–
51]. This study confirmed the safety of MQ with regard to
stillbirths, which has also been observed among HIV-negative
women [21,25].
In an exploratory analysis, the study also found that although
similar at baseline, HIV viral loads at delivery were significantly
higher in the women who received MQ than in those who received
placebo, and the proportion of infants who were perinatally
infected with HIV was also increased if their mothers received
MQ. The effect of MQ on HIV viral loads at delivery and on
MTCT was not assessed in the trial evaluating MQ for IPTp in
HIV-infected Beninese pregnant women, but the MTCT
frequency was too low (less than 1%), given the sample size of
the study population to carry out this analysis [23]. The
unexpected finding of increased viral loads in women in the MQ
group led us to conduct an exploratory analysis of the association
of MTCT of HIV by group and of the factors associated with it.
The reasons for these associations are yet to be elucidated, though
several hypotheses could be postulated. First, the association could
be related to a poorer adherence with PMTCT and ART
regimens in the MQ group. However, though adherence with
ARVs was associated with the risk of MTCT of HIV, no
differences were found between groups. Second, despite an
adequate adherence with ARVs, the increased frequency of
vomiting in the MQ group could have contributed to the
Table 9. Severity of reported vomiting and dizziness by treatment group.
Severity Grade Control MQ
n Percent n Percent
Vomiting related to medication
Milda 28 71.8 196 80.3
Moderateb 10 25.6 42 17.2
Severec 1 2.6 6 2.5
Dizziness related to medication
Milda 55 78.6 217 75.6
Moderateb 15 21.4 61 21.3
Severec 0 0.0 9 3.1
aMild: awareness of sign or symptom, but easily tolerated.
bModerate: discomfort enough to cause interference with usual activity.
cSevere: incapacitating with inability to work or perform usual activity or patients at risk of death at the time of the event.
doi:10.1371/journal.pmed.1001735.t009
Table 10. Mother to child transmission of HIV by treatment group.
Infant HIV PCR Resultsa Control MQ RR (95% CI) p-Value
n Percent n Percent
ITT [N= 855]
Positive 19 4.4 36 8.6 1.95 0.015
Negative 416 95.6 384 91.4 (1.14–3.33)
ATP [N= 754]
Positive 15 3.8 29 8.0 2.10 0.016
Negative 378 96.2 332 92.0 (1.15–3.84)
aMedian age 5.9 weeks (IQR 1.7). ITT analysis adjusted by country. ATP analysis adjusted by baseline variables: country, literacy, gestational age, gravidity, anemia,
middle upper arm circumference and CD4 counts at baseline. Interaction MQ6country = p-value 0.660 for ITT cohort, and 0.872 for ATP cohort.
doi:10.1371/journal.pmed.1001735.t010
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association with a higher frequency of MTCT due to a reduced
absorption of the ARVs. Nevertheless, MQ-related vomiting was
generally mild and transient and thus unlikely to have significantly
affected the absorption of drugs taken throughout pregnancy.
Third, an as yet undefined pharmacokinetic interaction between
MQ and the ARVs used for PMTCT and ART (see Table 10 for
the list of ARVs) could have resulted in lower efficacy to these
drugs [52]. Interestingly, despite the geographical overlap of
malaria and HIV in many countries and the challenging
management of the co-infection, information regarding pharma-
cokinetic drug interactions of antimalarial and ARVs is mainly
limited to artemisinin derivatives and in general indicates little
effect of the former on the pharmacokinetics of ARVs [53–57]. On
the other hand, an attenuation of immunization has been
described when MQ was administered concurrently with the live
attenuated Salmonella typhi oral vaccine indicating an immune-
modulator effect of MQ [58,59], which is supported by the use of
MQ in the treatment of progressive multifocal leukoencephalo-
pathy (a severe demyelinating disease that occurs in immunosup-
pressed individuals) with favourable outcomes [60–62]. Thus, MQ
might have played an immunemodulator role in study participants,
resulting in an increase in viral load and increased frequency of
MTCT of HIV. The main limitation of the findings on the
association of MQ with MTCT of HIV is the exploratory nature of
this analysis. However, these results suggest further studies on the
pharmacological interactions between antimalarials and ARV drugs
are needed given the enormous public health relevance of both
infections. Finally, this unexpected finding indicates that assessment
of MTCT of HIV should be included in studies evaluating the
efficacy and safety of antimalarials in HIV-infected pregnant
women.
An association of presumptive clinical malaria with increased
risk of MTCT of HIV has been reported [63]. In the current
study, it seemed contradictory that both clinical malaria and MQ
Table 11. Concomitant antiretroviral medication by treatment group (ITT cohort).
Drugs n (%) Control n (%) MQ
Zidovudine 391 (72.8) 368 (68.9)
Nevirapine 386 (71.9) 375 (70.2)
Lamivudine 347 (64.6) 345 (64.6)
Stavudine 64 (11.9) 70 (13.1)
Tenofovir Disproxil Fumarate 17 (3.2) 19 (3.6)
Efavirenz 4 (0.7) 9 (1.7)
Lopinavir 0 (0.0) 3 (0.6)
Ritonavir 0 (0.0) 3 (0.6)
Abacavir 2 (0.4) 1 (0.2)
Emtricitabine 0 (0.0) 1 (0.2)
doi:10.1371/journal.pmed.1001735.t011
Table 12. Multivariate analysis of risk factors for mother to child transmission of HIV.
Variable ITT ATP
RR CI 95% p-Value RR CI 95% p-Value
Treatment
MQ vs control 2.05 1.16–3.63 0.014 2.17 1.12–4.19 0.021
Viral load at delivery (copies/ml) 0.022 0.100
400–999 vs ,400 4.80 1.38–16.65 3.32 0.88–12.50
1,000–9,999 vs ,400 3.59 1.39–9.29 3.75 1.43–9.87
.9,999 vs ,400 5.82 2.01–16.84 3.62 1.14–11.51
No data vs ,400 2.78 0.80–9.74 1.22 0.16–9.20
Clinical malaria episodes in pregnancya 3.05 1.35–6.92 0.008 4.76 2.01–11.24 ,0.001
Maternal adherence to PMTCT or ART guidelines 0.010 0.042
Incompleteb vs completec 1.94 1.06–3.57 1.96 0.98–3.92
Nothingd vs complete 2.86 1.43–5.74 3.01 1.22–7.37
Median age of infants was 5.9 weeks (IQR 1.7) at the time of the HIV PCR test. Analysis adjusted by baseline variables: country, literacy, gestational age, gravidity, anemia,
middle upper arm circumference, CD4 counts and viral load. ITT analysis adjusted by country. ATP analysis adjusted by baseline variables: country, literacy, gestational
age, gravidity, anemia, middle upper arm circumference, CD4 counts, and viral load.
aAt least one episode of clinical malaria during study follow-up in pregnancy.
bIncomplete: received partially PMTCT (either antenatal, intrapartum, or postpartum) or ART.
cComplete: received PMTCT (antenatal, intrapartum, and postpartum) or ART according to national guidelines.
dThe mother did not receive either PMTCT or ART.
doi:10.1371/journal.pmed.1001735.t012
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were associated with an increased frequency of MTCT of HIV,
since MQ was also related with decreased malaria risk. Although
these associations could be due to chance, in the multivariate
model the effects of clinical malaria and MQ increasing the
frequency of perinatal MTCT of HIV were independent. The
independence of the two effects is supported by the fact that in
both the univariate and multivariate models the magnitude of each
association with MTCT of HIV was similar, and the interaction
was not significant. It could be hypothesized that this observed
increased frequency of MTCT in association with clinical malaria
is explained not by an effect of malaria itself but rather by
pharmacokinetic interactions between the artemisinin derivatives,
which the women received to treat malaria episodes, and the
ARVs taken for PMTCT or ART [56].
Cotrimoxazole prophylaxis was administered as a trial inter-
vention to all study participants following recommendations for
HIV-infected pregnant women in poor-resource settings [10]. The
overall observed adherence to CTXp was high with 75% of the
women taking more than 80% of the expected doses. There is very
little information on CTXp adherence during pregnancy; howev-
er, it is likely to be lower than reported in the context of this
clinical trial, and therefore the antimalarial prevention of CTXp in
pregnancy and its effectiveness may not be as high in real life
situations.
The majority (80%) of HIV-infected women in the world live in
Africa, 75% of them being younger than 25 years of age [64]. In
some countries hardest hit by the HIV epidemic, as many as 40%
of pregnant women are HIV-infected [3,6]. Many of these women
are also exposed to malaria infection and it is estimated that HIV
infection adds half a million malaria cases per year in pregnancy
[65]. As a result of the general immunosuppression the risks and
severity of malaria infection and disease is increased in HIV-
infected women, translating into more frequent and severe
placental infection as well as the loss of the parity pattern of
infection observed in non HIV-infected pregnant women [2,4].
Protection against malaria in this particularly vulnerable group of
the population needs further emphasis. Improved harmonization
between the two control programs as well as enhanced integration
of both HIV and malaria prevention activities within the
reproductive health program would help to address this issue.
Moreover, there is an urgent need to find additional drugs for
malaria prevention that are not contraindicated with the
concomitant administration of the drugs used to prevent
opportunistic infections in HIV-infected, malaria-exposed, preg-
nant women [4].
Conclusions
These results show that an effective antimalarial drug given as
IPTp can offer additional protection against malaria and some
associated adverse outcomes when added to CTXp and a LLITN,
improving malaria prevention and overall maternal health
through reduction in hospital admissions. However, because of
its poor tolerability at the dose of 15 mg/kg, MQ is not
recommended for IPTp [66]. In addition, the observed association
with an increased viral load at delivery and frequency of MTCT of
HIV raises further concern about its use in this context. The
benefits of improved malaria prevention in this particularly
vulnerable group of pregnant women highlight the need for
alternative drugs with better tolerability. Moreover, specifically
designed studies to fully understand the implications of co-
administration of antimalarials and ARVs are needed. Finally,
these results may also have implications regarding the antimalarial
drug combinations containing MQ currently recommended for
malaria treatment.
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Editors’ Summary
Background. Malaria, a mosquito-borne parasitic disease,
kills about 600,000 people every year. Most of these deaths
occur among young children living in sub-Saharan Africa
but pregnant women living in Africa are also very
vulnerable to malaria. Infection with malaria during preg-
nancy can cause severe maternal anemia (reduced red
blood cell numbers), stillbirths, and pre-term and low-
birthweight babies, and is responsible for the deaths of
many African women and their babies. To reduce the loss of
life from malaria in pregnancy, the World Health Organiza-
tion (WHO) recommends that pregnant women living in
Africa receive the antimalarial drug sulfadoxine-pyrimeth-
amine (SP) at each scheduled antenatal care visit given at
least a month apart (intermittent preventive treatment in
pregnancy [IPTp]). In addition, WHO advises pregnant
women to sleep under insecticide-treated bed nets to
protect themselves from the bites of infected mosquitoes
and recommends effective case management of pregnant
women with malarial illness.
Why Was This Study Done? Pregnant women living in
Africa are often infected with HIV, the virus that causes AIDS.
HIV infection increases both the risk and severity of malaria
infection during pregnancy, and at least one million
pregnancies are complicated by co-infection with malaria
and HIV in sub-Saharan Africa every year. WHO recommends
that HIV-positive pregnant women take cotrimoxazole (CTX)
daily to prevent opportunistic infections (CTX prophylaxis
[CTXp]). Unfortunately, both CTX and SP are antifolate drugs
and taking two drugs of this type increases a woman’s risk of
developing a severe skin reaction. Moreover, although CTXp
protects children and HIV-infected adults against malaria, it is
not known whether CTXp alone protects HIV-infected
pregnant women adequately against malaria. Thus, evalua-
tions of alternative drugs for use in IPTp in HIV-positive
pregnant women are needed. In this randomized placebo-
controlled trial, the researchers study the safety and efficacy
of the antimalarial drug mefloquine (MQ) in HIV-infected
women receiving CTXp. A randomized, placebo-controlled
trial compares outcomes among people chosen through the
play of chance to receive either the drug under investigation
or a ‘‘dummy’’ (placebo) drug.
What Did the Researchers Do and Find? The researchers
allocated 1,071 HIV-infected pregnant women from Kenya,
Mozambique, and Tanzania to receive three doses of MQ
(IPTp-MQ), given at least one month apart, or three doses of
placebo. All the women received CTXp and were given an
insecticide-treated bed net. In an intention-to-treat analysis
(an analysis that considers the outcomes of all trial
participants irrespective of whether they receive their
allocated treatment), the prevalence of parasitemia (parasites
in the blood) at delivery among women given IPTp-MQ was
3.5% whereas the prevalence among women given the
placebo was 6.9%. In other words, compared to placebo,
IPTp-MQ was associated with a reduced risk of maternal
parasitemia. IPTp-MQ was also associated with a reduced
rate of placental malaria (parasites in the placenta) and a
reduced incidence of hospital admissions for non-pregnancy
related causes. There was no difference in adverse pregnancy
outcomes such as stillbirth between the intervention groups
but drug tolerability was poorer in the MQ group than in the
placebo group. Finally, in an exploratory (unplanned)
according-to-protocol analysis (an analysis that only consid-
ers outcomes in trial participants who receive their allocated
intervention), women in the MQ group had a higher HIV viral
load at delivery than women in the control group and were
nearly twice as likely to transmit HIV to their child around the
time of birth.
What Do These Findings Mean? These findings suggest
that the addition of IPTp-MQ to CTXp and the use of
insecticide-treated bed nets can improve malaria prevention
and maternal health in HIV-infected pregnant women in
Africa. However, the poor tolerability of MQ and the
association of MQ treatment with both an increased HIV
viral load at delivery and a higher frequency of mother-to-
child-transmission of HIV when compared to placebo raise
concerns about the use of MQ in IPTp. Because these last
two findings came from an exploratory analysis, which is
more likely to throw up a chance finding than a pre-planned
analysis further studies are needed to confirm these
unexpected but potentially important findings. Nevertheless,
overall, the findings of this study suggest that MQ should not
be recommended for IPTp in HIV-infected pregnant women
in Africa and highlight the need to find alternative drugs for
malaria prevention in this group of women who are
particularly vulnerable to malaria.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001735.
N This study is further discussed in a PLOS Medicine
Perspective by Richard Steketee.
N A related PLOS Medicine Research Article by Gonza´lez et al.
compares the efficacy of IPTp-MQ and IPTp-SP in HIV-
negative women
N Information is available from the World Health Organiza-
tion on malaria (in several languages) and on malaria in
pregnancy; information on IPTp and the current WHO
policy recommendation on IPTp with SP are available; the
2013 World Malaria Report provides details of the current
global malaria situation
N The US Centers for Disease Control and Prevention also
provides information on malaria; a personal story about
malaria in pregnancy is available
N Information is available from the Roll Back Malaria
Partnership on all aspects of global malaria control,
including information on malaria in pregnancy
N The Malaria in Pregnancy Consortium is undertaking
research into the prevention and treatment of malaria in
pregnancy
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
N More information about the trial protocol is available
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